An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing

Clinical Rheumatology

Volumn 32, Issue 5, 2013, Pages 601-608

  Man, Ada ^a   Shojania, Kam ^b,c   Phoon, Carmen ^b   Pal, Jason ^b   De Badyn, Monika Hudoba ^b   Pi, David ^b   Lacaille, Diane ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

Antibodies; Antinuclear analysis; Autoantibodies analysis; Rheumatic diseases diagnosis; Serologic tests utilization; Unnecessary Procedures

Indexed keywords

ANTINUCLEAR ANTIBODY; CELL NUCLEUS ANTIGEN; DOUBLE STRANDED DNA; EXTRACTABLE NUCLEAR ANTIGEN; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CANADA; CLINICAL EVALUATION; CONSENSUS; COST CONTROL; HUMAN; IMMUNOASSAY; LABORATORY TEST; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST;

ALGORITHMS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, NUCLEAR; AUTOANTIBODIES; BRITISH COLUMBIA; COST-BENEFIT ANALYSIS; DNA; HEALTH CARE COSTS; HUMANS; LABORATORIES; PHYSICIAN'S PRACTICE PATTERNS; REGIONAL MEDICAL PROGRAMS; RETROSPECTIVE STUDIES; RHEUMATOLOGY;

EID: 84878724387     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2141-y     Document Type: Article

References (22)

1. Tan EM, Feltkamp TE, Smolen JS et al (1997) Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40(9):1601-1611
2. Tampoia M, Brescia V, Fontana A et al (2007) Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficacy in autoimmune rheumatic disease. Arch Pathol Lab Med 131(1):112-116
3. Solomon DH, Shmerling RH, Schur PH et al (1999) A computer based intervention to reduce unnecessary serologic testing. J Rheumatol 26(12):2578-2584
4. Bonaguri C, Melegari A, Dall'Aglio P et al (2009) An Italian multicenter study for application of a diagnostic algorithm in autoantibody testing. Ann N Y Acad Sci 1173:124-129
5. Wiik A, Cervera R, Haass M et al (2006) European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders. Lupus 15(7):391-396
6. Tozzoli R, Bizzaro N, Tonutti E et al (2002) Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 117(2):316-324
7. Stinton LM, Fritzler MJ (2007) A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmun Rev 7(1):77-84
8. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 124(1):71-81
9. Shojania K (2000) Rheumatology: 2. What laboratory tests are needed? CMAJ 162(8):1157-1163
10. Bizzaro N, Wiik A (2004) Appropriateness in anti-nuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol 22(3):349-355
11. Anon. (2001) Guidelines and protocols advisory committee - antinuclear antibody (ANA) testing for connective tissue disease. http://www.bcguidelines. ca/guideline-ana-testing.html. Accessed June 4, 2012.
12. Solomon DH, Kavanaugh AJ, Schur PH (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47(4):434-444
13. Avina-Zubieta JA, Sayre EC, Bernatsky S et al (2011) Adult Prevalence of Systemic Autoimmune Rheumatic Diseases (SARDs) in British Columbia. Can Arthritis Rheum 63(Suppl 10):1846
14. Anon. (2012) Population estimates, British Columbia and sub-provincial - BC stats. http://www.bcstats.gov.bc.ca/StatisticsBySubject/Demography/ PopulationEstimates.aspx. Accessed May 21, 2012.
15. Anon. (2012) Medical Services Plan home page. http://www.health.gov.bc. ca/msp/. Accessed July 24, 2012.
16. Wiik AS (2005) Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 34(4):260-268
17. Dahle C, Skogh T, Aberg AK, Jalal A, Olcén P (2004) Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun 22(3):241-248
18. Peene I, Meheus L, Veys E, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60(12):1131-1136
19. Damoiseaux JGMC, Tervaert JWC (2006) From ANA to ENA: how to proceed? Autoimmun Rev 5(1):10-17
20. Fritzler MJ, Miller BJ (1995) Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. J Clin Lab Anal 9(3):218-224
21. Fritzler MJ, Wiik A, Fritzler ML, Barr SG (2003) The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 5(4):192-201
22. Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69(8):1420-1422